TY - JOUR
T1 - Brafv600e hot spot mutation in thyroid carcinomas
T2 - First moroccan experience from a single-institution retrospective study
AU - Kaabouch, Meryem
AU - Chahdi, Hafsa
AU - Azouzi, Naima
AU - Oukabli, Mohammed
AU - Rharrassi, Issam
AU - Boudhas, Adil
AU - Jaddi, Hassan
AU - Ababou, Mouna
AU - Dakka, Nadia
AU - Boichard, Amélie
AU - Bakri, Youssef
AU - Dupuy, Corinne
AU - Al Bouzidi, Abderrahmane
AU - Ameziane El Hassani, Rabii
N1 - Publisher Copyright:
© 2020 Kaabouch M et al. Licensee African Health Sciences.
PY - 2020/1/1
Y1 - 2020/1/1
N2 - Background: The incidence of thyroid cancer is increasing worldwide at an alarming rate. BRAFV600E mutation is described to be associated with a worse prognostic of thyroid carcinomas, as well as extrathyroidal invasion and increased mortality. Objective: To our knowledge, there are no reported studies neither from Morocco nor from other Maghreb countries re-garding the prevalence of BRAFV600E mutation in thyroid carcinomas. Here we aim to evaluate the frequency of BRAFV600E oncogene in Moroccan thyroid carcinomas. Methods: In this Single-Institution retrospective study realized in the Anatomic Pathology and Histology Service in the Military Hospital of Instruction Mohammed V ‘HMIMV’ in Rabat, we report, using direct genomic sequencing, the assessment of BRAFV600E in 37 thyroid tumors. Results: We detected BRAFV600E mutation exclusively in Papillary Thyroid Carcinomas ‘PTC’ with a prevalence of 28% (8 PTC out 29 PTC). Like international trends, Papillary Thyroid Carcinomas ’PTC’ is more frequent than Follicular Thyroid Carcinomas ‘FTC’ and Anaplastic Thyroid Carcinomas ‘ATC’ (29 PTC, 7 FTC and 1 ATC). Conclusion: Our finding gives to the international community the first estimated incidence of this oncogene in Morocco showing that this prevalence falls within the range of international trends (30% to 90%) reported in distinct worldwide ge-ographic regions.
AB - Background: The incidence of thyroid cancer is increasing worldwide at an alarming rate. BRAFV600E mutation is described to be associated with a worse prognostic of thyroid carcinomas, as well as extrathyroidal invasion and increased mortality. Objective: To our knowledge, there are no reported studies neither from Morocco nor from other Maghreb countries re-garding the prevalence of BRAFV600E mutation in thyroid carcinomas. Here we aim to evaluate the frequency of BRAFV600E oncogene in Moroccan thyroid carcinomas. Methods: In this Single-Institution retrospective study realized in the Anatomic Pathology and Histology Service in the Military Hospital of Instruction Mohammed V ‘HMIMV’ in Rabat, we report, using direct genomic sequencing, the assessment of BRAFV600E in 37 thyroid tumors. Results: We detected BRAFV600E mutation exclusively in Papillary Thyroid Carcinomas ‘PTC’ with a prevalence of 28% (8 PTC out 29 PTC). Like international trends, Papillary Thyroid Carcinomas ’PTC’ is more frequent than Follicular Thyroid Carcinomas ‘FTC’ and Anaplastic Thyroid Carcinomas ‘ATC’ (29 PTC, 7 FTC and 1 ATC). Conclusion: Our finding gives to the international community the first estimated incidence of this oncogene in Morocco showing that this prevalence falls within the range of international trends (30% to 90%) reported in distinct worldwide ge-ographic regions.
KW - Biomarker
KW - BRAF
KW - Morocco
KW - Thyroid cancer
UR - http://www.scopus.com/inward/record.url?scp=85098083834&partnerID=8YFLogxK
U2 - 10.4314/ahs.v20i4.40
DO - 10.4314/ahs.v20i4.40
M3 - Article
C2 - 34394248
AN - SCOPUS:85098083834
SN - 1680-6905
VL - 20
SP - 1849
EP - 1856
JO - African Health Sciences
JF - African Health Sciences
IS - 4
ER -